SI kinase to act as a key signaling mediator of a rare fusion oncogene involved in fibrolamellar carcinoma

Kei Sakamoto, Vice Director of  Novo Nordisk Foundation, shared a post by Elizabeth McKenna, on X:

“Delighted to be a contributor of this very exciting work. Intriguing to see that the Salt-inducible kinase (SIK), one of AMPK-related kinases, acts as a key signaling mediator of a rare fusion oncogene involved in fibrolamellar carcinoma.”

Quoting Elizabeth McKenna’s post:

“Now online in Cancer Discovery:

DNAJB1-PRKACA Drives Fibrolamellar Liver Cancer via Impaired SIK Signaling and  CRTC2/p300-mediated Transcriptional Reprogramming.

Authors: Ilaria Gritti, Jinkai Wan, Vajira Weeresekara, Joel M. Vaz, Tenna Holgersen. Bryde, Giuseppe Tarantino,Vindhya Vijay, Ashwin V. Kammula, Prabhat Kattel, Songli Zhu, Phuong Vu, Marina Chan, Meng-Ju Wu, John D. Gordan, Krushna C. Patra, Vanessa S. Silveira, Robert T. Manguso, Marc N. Wein, Christopher J. Ott, Jun Qi, David Liu, Kei Sakamoto, Taranjit S. Gujral, Nabeel Bardeesy.”

Read further.
Source: Kei Sakamoto/X and Elizabeth McKenna/X

Elizabeth McKenna is the Executive Director of Cancer Discovery at the American Association for Cancer Research. Elizabeth earned her PhD from Harvard University and trained with Dr. Charles Roberts at the Dana-Farber Cancer Institute. Her research was among the first to show that pediatric tumors characterized by mutations in chromatin remodelers are genomically stable and instead driven by epigenetic deregulation of key target genes. She joined Cancer Discovery shortly after its launch as its founding Science Writer and became an editor in 2014, rising through the editorial ranks to become the journal’s Executive Editor in 2019. She is a member of the 40 Under 40 in Cancer Class of 2021.